GlassScriptPhysician profile
Whitney Ward Garrett
NPI 1407597818
$3,116.56
in general payments reported to CMS, 2019-2025
40 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $942 · 2023: $1,812 · 2024: $198 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.91 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $322.36 | 2022-2024 | Lynparza, Imfinzi, Andexxa |
| Seagen INC. | $246.71 | 2022-2023 | Tivdak, Tukysa, Padcev |
| Amgen INC. | $214.87 | 2022-2023 | Kyprolis, Blincyto, Lumakras |
| Merck Sharp & Dohme LLC | $176.50 | 2022-2023 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $168.11 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $129.43 | 2022-2023 | Opdivo, Pomalyst |
| Pfizer INC. | $127.95 | 2022-2024 | |
| Incyte Corporation | $122.73 | 2022-2023 | Jakafi |
| Beigene USA, INC. | $120.53 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $116.20 | 2023-2024 | Erleada, Darzalex |
| Sumitomo Pharma America, INC. | $104.32 | 2024-2025 | Gemtesa, Myfembree |
| Pharmacyclics LLC, An Abbvie Company | $94.70 | 2023 | Imbruvica |
| Celgene Corporation | $86.28 | 2022-2023 | Opdualag, Reblozyl |
| Daiichi Sankyo INC. | $79.24 | 2022-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $77.99 | 2022-2023 | Libtayo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $76.28 | 2022-2023 | Iclusig |
| Genentech USA, INC. | $74.38 | 2022-2023 | Venclexta, Phesgo |
| Karyopharm Therapeutics INC. | $74.35 | 2022-2023 | Xpovio |
| Hologic Sales and Service, LLC | $71.98 | 2023-2025 | Aptima, Novasure |
| Eisai INC. | $68.91 | 2022 | |
| Exeltis, USA INC. | $63.80 | 2025 | Slynd |
| Rigel Pharmaceuticals, INC. | $59.65 | 2023 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $48.25 | 2022-2023 | Fotivda |
| Astellas Pharma US INC | $46.79 | 2022 | |
| Lilly USA, LLC | $35.56 | 2023-2025 | Zepbound, Jaypirca, Verzenio |
| Myriad Genetic Laboratories, INC. | $32.05 | 2023 | Precisetumor |
| Glaxosmithkline, LLC. | $28.94 | 2022-2023 | Jemperli, Zejula |
| Exelixis INC. | $24.86 | 2023 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $24.54 | 2023 | Monoferric |
| Genzyme Corporation | $24.38 | 2022 | |
| Mirati Therapeutics, INC. | $23.64 | 2023 | Krazati |
| Sobi, INC | $19.12 | 2023 | |
| Immunogen, INC. | $18.77 | 2023 | Elahere |
| Cti Biopharma Corp. | $18.77 | 2023 | Vonjo |
| Puma Biotechnology, INC. | $18.44 | 2023 | |
| Adaptive Biotechnologies Corporation | $17.51 | 2023 | Clonoseq |
| Stemline Therapeutics INC. | $15.69 | 2023 | Orserdu |
| Exact Sciences Corporation | $14.19 | 2025 | Cologuard Collection Kit |
| G1 Therapeutics, INC. | $14.06 | 2023 | Cosela |
| Abbvie INC. | $13.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.